Short answer
PRECIGEN, INC. (PGEN) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$146M
- −510.3% YoY · −449.3% QoQ
- EPS (diluted)
- −$1.09
- −1262.5% YoY · −1111.1% QoQ
Source: XBRL data from the PRECIGEN, INC. (PGEN) Q3 2025 10-Q on SEC EDGAR. USD.
PRECIGEN, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2.922M, up >200% YoY from $953K, driven by $1.818M collaboration revenue
- Net loss $146.344M vs $23.978M; operating loss $34.481M vs $21.262M
- SG&A $23.991M, up 143.9% YoY, including $9.0M Papzimeos commercial-readiness costs
- Papzimeos full FDA approval in August 2025; management expects future product revenue, with near-term collaboration revenue minimal
Risk Factors
- New debt risk triggered by September 3, 2025 Loan Agreement, adding $100.0 million funded debt and $25.0 million delayed draw capacity
- Most material financial update: senior secured term loans mature September 3, 2030, with interest at three-month Term SOFR plus 6.50%
- Regulatory and compliance risk: covenant breaches could accelerate repayment and enable lenders to enforce liens on substantially all U.S. assets, including intellectual property
- Operational flexibility risk: minimum net sales, minimum liquidity, and restrictions on additional debt, investments, and asset transfers
- Near-term liquidity risk: quarterly interest payments and eight equal quarterly amortization installments beginning September 29, 2028્રીય
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PRECIGEN, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.